Sanofi Price to Sales Ratio 2010-2023 | SNY
Historical PS ratio values for Sanofi (SNY) over the last 10 years. The current P/S ratio for Sanofi as of April 23, 2024 is .
For more information on how our historical price data is adjusted see the Stock Price Adjustment Guide.
| Sanofi P/S Ratio Historical Data |
| Date |
Stock Price |
TTM Sales per Share |
Price to Sales Ratio |
| 2024-04-23 |
47.69 |
|
2.38 |
| 2023-12-31 |
49.73 |
$20.07 |
2.48 |
| 2023-09-30 |
53.64 |
$19.56 |
2.74 |
| 2023-06-30 |
53.90 |
$19.33 |
2.79 |
| 2023-03-31 |
52.44 |
$19.24 |
2.73 |
| 2022-12-31 |
46.67 |
$19.09 |
2.44 |
| 2022-09-30 |
36.64 |
$19.45 |
1.88 |
| 2022-06-30 |
48.21 |
$14.17 |
3.40 |
| 2022-03-31 |
47.88 |
$13.89 |
3.45 |
| 2021-09-30 |
44.96 |
$13.98 |
3.22 |
| 2021-06-30 |
49.11 |
$12.99 |
3.78 |
| 2021-03-31 |
44.44 |
$17.40 |
2.55 |
| 2020-09-30 |
45.08 |
$17.07 |
2.64 |
| 2020-03-31 |
37.91 |
$16.47 |
2.30 |
| 2019-09-30 |
40.17 |
$16.54 |
2.43 |
| 2019-03-31 |
36.85 |
$16.54 |
2.23 |
| 2018-03-31 |
31.84 |
$16.48 |
1.93 |
| 2017-12-31 |
34.16 |
$16.30 |
2.10 |
| 2017-09-30 |
39.55 |
$16.15 |
2.45 |
| 2017-06-30 |
38.06 |
$15.40 |
2.47 |
| 2016-12-31 |
31.07 |
$14.89 |
2.09 |
| 2016-09-30 |
29.34 |
$15.19 |
1.93 |
| 2016-06-30 |
32.16 |
$15.17 |
2.12 |
| 2016-03-31 |
29.60 |
$15.77 |
1.88 |
| 2015-09-30 |
34.98 |
$16.30 |
2.15 |
| 2015-06-30 |
36.50 |
$16.63 |
2.20 |
| 2014-06-30 |
37.95 |
$16.88 |
2.25 |
| 2013-06-30 |
35.49 |
$17.03 |
2.08 |
| 2012-06-30 |
25.15 |
$17.62 |
1.43 |
| 2012-03-31 |
24.65 |
$17.83 |
1.38 |
| 2011-12-31 |
23.24 |
$17.94 |
1.30 |
| 2011-09-30 |
20.86 |
$17.40 |
1.20 |
| 2011-06-30 |
25.55 |
$17.02 |
1.50 |
| 2011-03-31 |
21.65 |
$16.45 |
1.32 |
| 2010-12-31 |
19.81 |
$15.82 |
1.25 |
| 2010-09-30 |
20.44 |
$15.82 |
1.29 |
| 2010-06-30 |
18.48 |
$15.87 |
1.16 |
| 2010-03-31 |
22.15 |
$15.83 |
1.40 |
| 2009-12-31 |
23.29 |
$15.62 |
1.49 |
| 2009-09-30 |
21.91 |
$15.51 |
1.41 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$119.271B |
$46.611B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
